Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma

A Randomized, Parallel, Open-Label Study to Compare the Pharmacokinetics of Ipilimumab (BMS-734016) Process C to Process B in Subjects With Advanced Melanoma

The purpose of this clinical research study is to compare pharmacokinetics of ipilimumab manufactured by two different processes

Inclusion Criteria:

• Histologic diagnosis of malignant melanoma
• Eastern Cooperative Oncology Group (ECOG) performance status 0-1
• Measurable/evaluable disease per modified World Health Organization (mWHO) criteria

Exclusion Criteria:

• Active Brain Metastasis
• Primary ocular or mucosal melanoma
• Prior Autoimmune disease
• Inadequate hematologic, hepatic or renal function
• Use of immunosuppressants
• Prior treatment with a CD137 agonist or cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitor